Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • Transmission Dynamics of Carbapenemase Genes in CREC in Chin

    2026-07-16

    Transmission Dynamics of Carbapenemase-Encoding Genes in Carbapenem-Resistant Enterobacter cloacae: Insights from Guangdong Hospitals

    Study Background and Research Question

    The global rise of carbapenem-resistant Enterobacteriaceae (CRE) poses a critical threat to public health, particularly in hospital settings. Among CRE, Enterobacter cloacae complex (CREC) has emerged as a major concern in China, ranking third in detection after Klebsiella pneumoniae and Escherichia coli. The COVID-19 pandemic has further complicated antimicrobial resistance patterns, due to increased antibiotic usage and disruptions in standard infection control. However, the specific genetic landscape and transmission dynamics of carbapenemase-encoding genes (CEGs) in CREC during this period remain underexplored. The reference study (Chen et al., 2025) addresses this gap by analyzing 54 CREC isolates from multiple teaching hospitals in Guangdong Province, collected between December 2022 and June 2024.

    Key Innovation from the Reference Study

    Chen et al. provide a comprehensive dissection of both the genetic content and epidemiological spread of CEGs in a contemporary clinical context. The key innovation lies in their dual focus: (1) high-resolution characterization of CEG localization (chromosome vs. plasmid), and (2) quantification of horizontal transfer potential using rigorous plasmid conjugation assays. This approach illuminates not only the prevalence but also the mobility and clinical implications of multidrug resistance determinants during and after the COVID-19 pandemic.

    Methods and Experimental Design Insights

    The study utilized a multi-tiered methodology to ensure robust and reproducible findings. First, 54 CREC isolates were collected from eight geographically distributed tertiary hospitals, ensuring diverse representation. Genomic DNA was extracted, and CEG presence was determined via PCR targeting blaNDM-1, blaIMP, and blaKPC-2 genes. To distinguish chromosomal versus plasmid localization, the variable temperature SDS plasmid elimination method was employed. Broth microdilution assays established antimicrobial susceptibility profiles. Plasmid conjugation experiments assessed the transferability of resistance determinants, while mobile genetic elements were identified and classified. Genotypic diversity and relationships were further analyzed using ERIC-PCR and NTSYS software.

    Protocol Parameters

    • Isolate collection: 54 CREC strains from eight teaching hospitals, December 2022–June 2024.
    • Genotype identification: PCR for blaNDM-1, blaIMP, blaKPC-2; ERIC-PCR for strain typing.
    • Plasmid elimination: Variable temperature SDS method to distinguish plasmid vs. chromosomal gene carriage.
    • Antibiotic susceptibility: Broth microdilution for imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, levofloxacin.
    • Transfer experiments: Plasmid conjugation followed by PCR to detect successful CEG transmission.

    Core Findings and Why They Matter

    The study revealed a high overall prevalence of CEGs (85.19%) among CREC isolates. Notably, the blaNDM-1 gene dominated, residing on both chromosomes and plasmids in 33.33% of isolates, and exclusively on plasmids in 46.30%. The blaIMP gene was rare (3.70%), and co-occurrence of blaNDM-1 and blaKPC-2 on plasmids was observed in a single case (1.85%). Strains with CEGs displayed significantly elevated resistance to multiple antibiotics, including ceftazidime/avibactam and fluoroquinolones.

    The plasmid conjugation experiments demonstrated a remarkably high horizontal transfer potential: 95.65% of CEG-positive isolates were able to transfer CEGs to recipient strains under laboratory conditions, with blaNDM-1 and blaIMP transfer rates near 100%. Six different mobile genetic elements were detected, with ISEcp1 being most prevalent (87.04%). Genotypic analysis categorized the strains into 17 groups, with two types (E and G) accounting for 40% of isolates, suggesting local clonal expansion and interdepartmental spread.

    Epidemiologically, the highest rates of CEG-positive CREC were found in elderly male patients, respiratory medicine departments, and sputum specimens, underlining the clinical importance for the treatment of bacterial pneumonia and bronchitis. The study underscores the urgency of targeted infection control and antimicrobial stewardship in high-risk hospital environments.

    Comparison with Existing Internal Articles

    Recent internal reviews of Ceftazidime as a third-generation cephalosporin highlight its efficacy against Gram-negative bacteria, including Pseudomonas aeruginosa, and its β-lactamase-resistant profile, making it a mainstay for the treatment of bacterial pneumonia and bronchitis. However, these articles also note the importance of continuous monitoring due to emerging resistance mechanisms. The present study provides direct genetic evidence of how multidrug resistance—especially through mobile CEGs—can undermine the reliability of ceftazidime and related antibiotics, even those with robust β-lactamase resistance. This highlights the need for genetic surveillance as a complement to traditional phenotypic assays in Gram-negative bacterial infection research.

    For researchers optimizing infection models, resources such as protocol guides for ceftazidime use recommend careful strain selection and incorporation of resistance data, echoing the reference study's emphasis on understanding local genetic contexts.

    Limitations and Transferability

    While the Guangdong-based surveillance is comprehensive, the findings may not fully generalize to other regions with different antimicrobial usage patterns or infection control practices. The study is also limited by its sample size and focus on tertiary hospitals, potentially overlooking dynamics in community or rural settings. The absence of whole-genome sequencing restricts resolution of some genetic relationships and mobility elements. However, the core demonstration of high-frequency CEG transfer and its clinical implications should inform both local and broader Gram-negative infection management strategies.

    Research Support Resources

    Researchers investigating Gram-negative resistance mechanisms or developing infection models can use Ceftazidime (SKU B3539) as a reference third-generation cephalosporin. Its well-characterized activity against Pseudomonas aeruginosa and β-lactamase-producing Enterobacteriaceae, as described in the product information, makes it suitable for experimental workflows assessing multidrug resistance emergence. Accurate storage and handling, as well as alignment with current genetic surveillance findings, will help ensure assay reliability. For advanced protocol optimization and troubleshooting in Gram-negative infection research, researchers are encouraged to integrate both phenotypic and genotypic resistance data, as underscored by the reference study and related internal resources.